TD Cowen analyst Gary Taylor lowered the firm’s price target on Privia Health to $35 from $44 and keeps an Outperform rating on the shares. The firm lowered EBITDA to accommodate higher platform costs in new markets OH CT NC & WA.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRVA:
- Privia Health reports Q2 non-GAAP EPS 17c, consensus 6c
- Privia Health Reports Second Quarter 2023 Financial Results
- Privia Health signs agreement to enter state of Washington
- Privia Health Announces Changes to Board of Directors
- Privia Health appoints David Wichmann, Pamela Kimmet to board of directors